Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia

Dopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. Each antipsychotic induces a unique pattern in leukocyte function and phenotype. However, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (PBMCs). The aim of this study was to evaluate the changes in the expression of D , D , DAT, 5-HT , and SERT in PBMCs from healthy volunteers (HV), drug-naive patients with schizophrenia (PWS), drug-free PWS, and PWS treated with risperidone for up to 40 weeks using quantitative PCR. Our study revealed elevated mRNA levels of D , DAT, 5-HT , and SERT in unmedicated PWS. Treatment with risperidone led to a reduction only in the expression of 5-HT and SERT. Furthermore, we observed a moderate correlation between 5-HT expression and the positive and negative syndrome scale (PANSS), as well as SERT expression and PANSS scale. We also found a moderate correlation between 5-HT and SERT expression and the positive subscale. The duration of risperidone consumption had a significant negative correlation with the expression of 5-HT and SERT. Our study introduces the measurement of 5-HT and SERT expression in PBMCs as a useful parameter for assessing the response to risperidone in PWS.